Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03040141
Registration number
NCT03040141
Ethics application status
Date submitted
23/01/2017
Date registered
2/02/2017
Date last updated
28/12/2022
Titles & IDs
Public title
Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A
Query!
Scientific title
Phase 2b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of IV VIS410 in Addition to Oseltamivir Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support
Query!
Secondary ID [1]
0
0
VIS410-203
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Influenza A
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Low dose of VIS410
Treatment: Drugs - High dose of VIS410
Treatment: Drugs - Placebo
Experimental: VIS410 low dose - Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
Experimental: VIS410 high dose - Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
Placebo Comparator: Placebo - Single intravenous infusion of placebo in addition to oseltamivir
Treatment: Drugs: Low dose of VIS410
Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
Treatment: Drugs: High dose of VIS410
Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
Treatment: Drugs: Placebo
Single intravenous infusion of placebo in addition to oseltamivir
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Clinical Status of Participants on Day 7
Query!
Assessment method [1]
0
0
Evaluate the effect of 2 dose levels of VIS410 + oseltamivir on clinical status using a seven-level ordinal scale. Comparison between treatment groups and between all VIS410 recipients versus placebo were assessed.
Query!
Timepoint [1]
0
0
7 days
Query!
Primary outcome [2]
0
0
The Number of Participants With Adverse Events and Serious Adverse Events Following Administration of VIS410
Query!
Assessment method [2]
0
0
Safety and tolerability of 2 dose levels of a single intravenous (IV) dose of VIS410 when administered in combination with oseltamivir in hospitalized participants with influenza A infection. Data presents the count of participants who experienced an adverse event (AE) or serious treatment emergent adverse events (TEAE).
Query!
Timepoint [2]
0
0
56 days
Query!
Secondary outcome [1]
0
0
Time to Cessation of Oxygen Support Compared to Oseltamivir Alone Among Patients Requiring Supplemental Oxygen Therapy With Baseline Room Air <= 92%
Query!
Assessment method [1]
0
0
Time to cessation of O2 support in patients with supplemental oxygen with baseline room air <= 92%. Patients with treatment resulting in a stable SpO2 by pulse oximetry. Stable SpO2 is defined as two consecutive SpO2 values of >92% on room air that are at least 8 hours apart.
Query!
Timepoint [1]
0
0
Baseline to Day 56
Query!
Secondary outcome [2]
0
0
Time to Cessation of Oxygen Support for Any Patient Requiring Supplemental Oxygen Therapy
Query!
Assessment method [2]
0
0
Time to cessation of oxygen support in all patients with supplemental oxygen (regardless of oxygen saturation).
Query!
Timepoint [2]
0
0
Baseline to Day 56
Query!
Secondary outcome [3]
0
0
Viral Titer in Upper Respiratory Samples by qRT-PCR
Query!
Assessment method [3]
0
0
The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in peak viral load by qRT-PCR from nasopharyngeal swabs through Day 14
Query!
Timepoint [3]
0
0
Day 14
Query!
Secondary outcome [4]
0
0
Viral Nasopharyngeal AUC
Query!
Assessment method [4]
0
0
The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in nasopharyngeal qRT-PCR area under the viral load-time curve (AUC) from baseline to Day 5.
Query!
Timepoint [4]
0
0
Day 1 Predose, Day 1 End of Infusion, Day 3, Day 5
Query!
Secondary outcome [5]
0
0
Area Under the Viral Load-Time Curve (VL AUC) Based on qRT-PCR From Nasopharyngeal Swabs Through Day 7
Query!
Assessment method [5]
0
0
The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in nasopharyngeal qRT-PCR area under the viral load-time curve (AUC) from baseline to Day 7.
Query!
Timepoint [5]
0
0
Day 1 Predose, Day 1 End of Infusion, Day 3, Day 5, Day 7
Query!
Secondary outcome [6]
0
0
Area Under the Viral Load-Time Curve (VL AUC) Based on qRT-PCR From Nasopharyngeal Swabs Through Day 14
Query!
Assessment method [6]
0
0
The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in nasopharyngeal qRT-PCR area under the viral load-time curve (AUC) from baseline to Day 14.
Query!
Timepoint [6]
0
0
Day 1 Predose, Day 1 End of Infusion, Day 3, Day 5, Day 7, Day 14
Query!
Secondary outcome [7]
0
0
Median Time to Resolution of Viral Load by Treatment Arm by qRT-PCR - From End of Infusion
Query!
Assessment method [7]
0
0
Number of days from the end of infusion until virus is no longer detectable (at or below the limit of detection) with no samples following that are greater than the BLQ through the Day 14 (quantitative reverse-transcription polymerase chain reaction - qRT-PCR)
Query!
Timepoint [7]
0
0
14 days
Query!
Secondary outcome [8]
0
0
Number of Participants in Whom Peak Viral Load Occurred Post Baseline Measured by qRT-PCR
Query!
Assessment method [8]
0
0
Number of participants in whom peak viral load is observed post-baseline based on quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Post-baseline was considered the day 3 sample or later.
Query!
Timepoint [8]
0
0
14 days
Query!
Secondary outcome [9]
0
0
Peak Viral Load by TCID50
Query!
Assessment method [9]
0
0
Peak viral load based on TCID50 from nasopharyngeal swabs
Query!
Timepoint [9]
0
0
Day 7
Query!
Secondary outcome [10]
0
0
Number of Participants in Whom Peak Viral Load Occurred Post Baseline Measured by TCID50
Query!
Assessment method [10]
0
0
Number of participants in whom peak viral load occurred post-baseline measured by TCID50. Post-baseline was considered the day 3 sample or later.
Query!
Timepoint [10]
0
0
56 days
Query!
Secondary outcome [11]
0
0
Viral Nasopharyngeal AUC by TCID50
Query!
Assessment method [11]
0
0
The area under the viral load-time curve (AUC) for VIS410 + oseltamivir and oseltamivir alone treatment groups from baseline to Day 5 measured by TCID50 from nasopharyngeal swabs.
Query!
Timepoint [11]
0
0
5 days
Query!
Secondary outcome [12]
0
0
Viral Nasopharyngeal AUC by TCID50
Query!
Assessment method [12]
0
0
The area under the viral load-time curve (AUC) for VIS410 + oseltamivir and oseltamivir alone treatment groups from baseline to Day 7 measured by TCID50 from nasopharyngeal swabs.
Query!
Timepoint [12]
0
0
7 days
Query!
Secondary outcome [13]
0
0
Negative Viral Cultures by Study Day
Query!
Assessment method [13]
0
0
Number of participants negative for viral titer by study day determined by TCID50 on nominal days 3, 5, 7
Query!
Timepoint [13]
0
0
Nominal days 3, 5, 7
Query!
Secondary outcome [14]
0
0
Median Time to Resolution of Viral Load by Treatment Arm by TCID50 - From End of Infusion
Query!
Assessment method [14]
0
0
Number of days from the end of infusion until virus is no longer detectable (at or below the limit of detection) with no samples following that are greater than the BLQ through the Day 7 (TCID50)
Query!
Timepoint [14]
0
0
7 Days
Query!
Secondary outcome [15]
0
0
Median Time to Resolution of Viral Load by Treatment Arm by TCID50 - From Onset of Symptoms
Query!
Assessment method [15]
0
0
Number of days from the onset of symptoms until virus is no longer detectable (at or below the limit of detection) with no samples following that are greater than the BLQ through the Day 7 (TCID50)
Query!
Timepoint [15]
0
0
7 Days
Query!
Secondary outcome [16]
0
0
Time to Clinical Response (4 Out of 5 Vital Signs)
Query!
Assessment method [16]
0
0
Median time to clinical response defined by resolution of at least 4 of 5 vital signs:
Afebrile with core temperature = 37.8°C, without use of antipyretics (oral = 37.2°C)
Oxygen saturation = 95% on room air without support or a return to preinfection status, if pre-infection status was < 95%
Pulse rate = 100/min
Systolic blood pressure = 90 mm/Hg, without vasopressor use
Respiratory rate = 24 beats per minute
Query!
Timepoint [16]
0
0
Day 56
Query!
Secondary outcome [17]
0
0
Time to Complete Clinical Response (Resolution of All Vital Signs)
Query!
Assessment method [17]
0
0
Median time to clinical response defined by resolution of at all 5 vital signs:
Afebrile with core temperature = 37.8°C, without use of antipyretics (oral = 37.2°C)
Oxygen saturation = 95% on room air without support or a return to pre-infection status, if pre-infection status was < 95%
Pulse rate = 100/min
Systolic blood pressure = 90 mm/Hg, without vasopressor use
Respiratory rate = 24 beats per minute
Query!
Timepoint [17]
0
0
Day 56
Query!
Secondary outcome [18]
0
0
Clinical Status Ordinal Scale Mean Area Under the Curve Through Day 7
Query!
Assessment method [18]
0
0
Summary of area under the curve (AUC) over time for seven-level ordinal scale. Area under the curve (AUC) is calculated using the linear trapezoidal rule. Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities. Time frame is from baseline to day 7. Therefore, maximum and minimum values possible for the AUC Clinical Status Ordinal Scale scores range from 7 to 49.
Query!
Timepoint [18]
0
0
Baseline to Day 7
Query!
Secondary outcome [19]
0
0
Clinical Status Ordinal Scale Mean Area Under the Curve Through Day 14.
Query!
Assessment method [19]
0
0
Summary of area under the curve (AUC) over time for seven-level ordinal scale. Area under the curve (AUC) is calculated using the linear trapezoidal rule. Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities. Time frame is from baseline to day 14. Therefore, maximum and minimum values possible for the AUC Clinical Status Ordinal Scale scores range from 14 to 98.
Query!
Timepoint [19]
0
0
Baseline to Days 14
Query!
Secondary outcome [20]
0
0
Comparison of Clinical Status on Seven-level Ordinal Scale Scores
Query!
Assessment method [20]
0
0
Summary of Clinical Outcome on Seven-Level Ordinal Scale through Day 14. Worst post-baseline assessment observed.
Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.
Query!
Timepoint [20]
0
0
Day 14
Query!
Secondary outcome [21]
0
0
Total Number of Days on Ventilation
Query!
Assessment method [21]
0
0
Total number of days on ventilation for participants who used ventilation, including participants on ventilation at baseline
Query!
Timepoint [21]
0
0
56 days
Query!
Secondary outcome [22]
0
0
Comparison of Ordinal Scale Parameters - Days on Ventilation
Query!
Assessment method [22]
0
0
Total number of days on ventilation for participations who used ventilation, including participants on ventilation at baseline. Better and worse outcome groups defined based on the Seven-Level Ordinal Scale scores, "<= 4 Seven-Level Ordinal Scale Score" is better; "> 4 Seven-Level Ordinal Scale Score" is worse group.
Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.
Query!
Timepoint [22]
0
0
56 days
Query!
Secondary outcome [23]
0
0
Total Number of Days in ICU
Query!
Assessment method [23]
0
0
Total number of days in intensive care (ICU) for participants who admitted to the ICU, including participants in ICU at baseline
Query!
Timepoint [23]
0
0
56 days
Query!
Secondary outcome [24]
0
0
Comparison of Ordinal Scale Parameters - Days in ICU
Query!
Assessment method [24]
0
0
Total number of days in intensive care for participants who admitted to ICU, including participants in ICU at baseline. Better and worse outcome groups defined based on the Seven-Level Ordinal Scale scores, "<= 4 Seven-Level Ordinal Scale Score" is better; "> 4 Seven-Level Ordinal Scale Score" is worse group.
Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.
Query!
Timepoint [24]
0
0
56 days
Query!
Secondary outcome [25]
0
0
Number of Days to Resumption of Usual Activities
Query!
Assessment method [25]
0
0
Number of days until resumption of usual activities by treatment group
Query!
Timepoint [25]
0
0
Day 56
Query!
Secondary outcome [26]
0
0
All Cause and Attributable Mortality at Day 14
Query!
Assessment method [26]
0
0
Number of patients experiencing all-cause and attributable mortality rates at Day 14. Attributable mortality was derived from the Complication of Influenza eCRF; all-cause mortality was derived from Complication of Influenza, Seven-Level Ordinal Scale, AE and Study Completion eCRFs
Query!
Timepoint [26]
0
0
Day 14
Query!
Secondary outcome [27]
0
0
All Cause and Attributable Mortality by Day 28
Query!
Assessment method [27]
0
0
Number of patients experiencing all-cause and attributable mortality by Day 28. Attributable mortality was derived from the Complication of Influenza eCRF; all-cause mortality was derived from Complication of Influenza, Seven-Level Ordinal Scale, AE and Study Completion eCRFs
Query!
Timepoint [27]
0
0
Day 28
Query!
Secondary outcome [28]
0
0
All Cause and Attributable Mortality Day 56
Query!
Assessment method [28]
0
0
Number of patients experiencing all-cause and attributable mortality by Day 56. Attributable mortality was derived from the Complication of Influenza eCRF; all-cause mortality was derived from Complication of Influenza, Seven-Level Ordinal Scale, AE and Study Completion eCRFs
Query!
Timepoint [28]
0
0
Day 56
Query!
Secondary outcome [29]
0
0
Healthcare Resource Utilization. Days in Hospital and/or ICU
Query!
Assessment method [29]
0
0
Total number of days in hospital and/or ICU from admission to discharge
Query!
Timepoint [29]
0
0
Day 56
Query!
Secondary outcome [30]
0
0
Comparison of Ordinal Scale Parameters - Days in Hospital/ICU
Query!
Assessment method [30]
0
0
Total number of days in hospital or intensive care for participations who were admitted to Hospital/ICU, including participants in Hospital/ICU at baseline. Better and worse outcome groups defined based on the Seven-Level Ordinal Scale scores, "<= 4 Seven-Level Ordinal Scale Score" is better; "> 4 Seven-Level Ordinal Scale Score" is worse group.
Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.
Query!
Timepoint [30]
0
0
56 days
Query!
Secondary outcome [31]
0
0
Number of Participants With Rehospitalization Due to Relapse
Query!
Assessment method [31]
0
0
Number of participants with rehospitalization due to influenza A relapse
Query!
Timepoint [31]
0
0
Day 56
Query!
Secondary outcome [32]
0
0
Number of Participants With Influenza-related Complications
Query!
Assessment method [32]
0
0
Summary of influenza symptom complications, including baseline and incident complications
Query!
Timepoint [32]
0
0
Day 56
Query!
Secondary outcome [33]
0
0
The Maximum Concentration (Cmax) of VIS410 in Participant's Serum
Query!
Assessment method [33]
0
0
Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by maximum concentration (Cmax) of VIS410 in participant's serum.
Query!
Timepoint [33]
0
0
Baseline, end of infusion, Day 5, Day 14, Day 28, Day 56
Query!
Secondary outcome [34]
0
0
The Area Under the Concentration/Time Curve of VIS410 in Participant's Serum
Query!
Assessment method [34]
0
0
Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by the area under the concentration/time curve from 0 to infinity (AUC0-inf) of VIS410 in participant's serum.
Query!
Timepoint [34]
0
0
Baseline, end of infusion, Day 5, Day 14, Day 28, Day 56
Query!
Secondary outcome [35]
0
0
The Clearance Rate (Cl) of VIS410 in Participant's Serum
Query!
Assessment method [35]
0
0
Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by the clearance rate (Cl) of VIS410 in participant's serum.
Query!
Timepoint [35]
0
0
PK samples were collected on days 1, 5, 14, 28 and 56.
Query!
Secondary outcome [36]
0
0
The Half-life of VIS410 in Participant's Serum
Query!
Assessment method [36]
0
0
Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by the half-life (t1/2) of VIS410 in participant's serum.
Query!
Timepoint [36]
0
0
PK samples were collected on days 1, 5, 14, 28 and 56.
Query!
Secondary outcome [37]
0
0
Anti-VIS410 Antibody Testing
Query!
Assessment method [37]
0
0
Summary of the maximum fold increase for anti-VIS410 antibody testing for VIS410 groups and placebo.
Query!
Timepoint [37]
0
0
From anti-VIS410 antibody samples collected on days 28 and 56.
Query!
Eligibility
Key inclusion criteria
- Male and female subjects aged = 18 years.
- Test positive for influenza A by rapid antigen test or with another commercially
available test on an adequate nasopharyngeal specimen in accordance with the
manufacturer's instructions, or an acceptable local test, including PCR (Polymerase
chain reaction), FIA (Fluorescent immunoassay), or ELISA
- Onset of influenza symptoms no more than 5 days before VIS410/placebo infusion;
symptoms may include cough, dyspnea, sore throat, fever, myalgias, headache, nasal
symptoms (rhinorrhea, congestion), fatigue, diarrhea, anorexia, nausea, and vomiting.
- Requirement for oxygen support including any positive pressure ventilation
- Women of childbearing potential must have a negative pregnancy test within 2 days
prior to VIS410/placebo infusion.
- Women should fulfill one of the following criteria:
- Post-menopausal; either amenorrhea = 12 months or follicle stimulating hormone >
40 mIU/mL as documented in their medical history
- Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation
- Women of childbearing potential participating in heterosexual sexual relations
must be willing to use adequate contraception from screening until 60 days post
VIS410/placebo infusion.
- Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects
who have a female partner of childbearing potential must use an effective birth
control method from screening until 60 days post VIS410/placebo infusion.
- Subject, or a legally acceptable representative (LAR), is able to understand the
purpose and risks of the study and willing to give voluntary written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Known or suspected intolerance or hypersensitivity to VIS410, oseltamivir,
pretreatment medications (diphenhydramine, or to both ibuprofen and acetylsalicylic
acid [ASA]), or closely related compounds (eg, other monoclonal antibodies)
- Subjects who have received VIS410 in the past
- History of receiving monoclonal antibody products (including VIS410) within 3 months
prior to VIS410/placebo dosing or planned administration during the study period
- Subjects who have taken more than 6 doses of an approved antiviral therapy for
influenza within the prior 96 hours (eg, oral oseltamivir, inhaled zanamivir, IV
peramivir, or oral ribavirin) between onset of symptoms and VIS410/placebo dosing
- Subjects with known co-infection with influenza B or other viral respiratory
infections (e.g., respiratory syncytial virus, parainfluenza viruses, respiratory
adenoviruses)
- Subjects with lung transplant or history of severe chronic lung disease, including
cystic fibrosis or any condition requiring home oxygen therapy
- Subjects on extracorporeal membrane oxygenation (ECMO) at time of randomization
- Subjects with end stage renal disease who are not undergoing hemodialysis
- Subjects with active graft-vs-host disease, hematopoietic stem cell transplant within
the previous 90 days, or human immunodeficiency virus infection with a CD4 cell count
of less than 200 per cubic millimeter
- Hospitalization for > 48 hours prior to randomization
- High probability of mortality within 48 hours of randomization as determined by the
Investigator
- Subjects weighing less than 45 kg
- Enrollment in any other investigational drug or device study, any disease or vaccine
study within 30 days prior to Day 1 or within 5 half-lives of the investigational
compound, whichever is longer
- Known or suspected alcohol or drug abuse, that is, abuse of a level that would
compromise the safety or cooperation of the subject in the opinion of the Investigator
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/01/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/11/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
89
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
Visterra - Adelaide
Query!
Recruitment hospital [2]
0
0
Visterra - Melbourne
Query!
Recruitment hospital [3]
0
0
Visterra - Parkville
Query!
Recruitment hospital [4]
0
0
Visterra - South Brisbane
Query!
Recruitment hospital [5]
0
0
Visterra - Westmead
Query!
Recruitment hospital [6]
0
0
Visterra - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3168 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [6]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Montana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Washington
Query!
Country [15]
0
0
Belarus
Query!
State/province [15]
0
0
Brest
Query!
Country [16]
0
0
Belarus
Query!
State/province [16]
0
0
Gomel
Query!
Country [17]
0
0
Belarus
Query!
State/province [17]
0
0
Grodno
Query!
Country [18]
0
0
Belarus
Query!
State/province [18]
0
0
Lesnoy
Query!
Country [19]
0
0
Belarus
Query!
State/province [19]
0
0
Minsk
Query!
Country [20]
0
0
Belarus
Query!
State/province [20]
0
0
Vitebsk
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Brussels
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Edegem
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Kozloduy
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Montana
Query!
Country [25]
0
0
Bulgaria
Query!
State/province [25]
0
0
Plovdiv
Query!
Country [26]
0
0
Bulgaria
Query!
State/province [26]
0
0
Sofia
Query!
Country [27]
0
0
Bulgaria
Query!
State/province [27]
0
0
Veliko Tarnovo
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
New Brunswick
Query!
Country [29]
0
0
Estonia
Query!
State/province [29]
0
0
Pärnu
Query!
Country [30]
0
0
Estonia
Query!
State/province [30]
0
0
Tallinn
Query!
Country [31]
0
0
Estonia
Query!
State/province [31]
0
0
Tartu
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
La Roche-sur-Yon
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
La Tronche
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Limoges
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Metz-Tessy
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Nantes
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Paris
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Quimper
Query!
Country [39]
0
0
Georgia
Query!
State/province [39]
0
0
Tbilisi
Query!
Country [40]
0
0
Latvia
Query!
State/province [40]
0
0
Daugavpils
Query!
Country [41]
0
0
Latvia
Query!
State/province [41]
0
0
Liepaja
Query!
Country [42]
0
0
Latvia
Query!
State/province [42]
0
0
Riga
Query!
Country [43]
0
0
Latvia
Query!
State/province [43]
0
0
Rezekne
Query!
Country [44]
0
0
Latvia
Query!
State/province [44]
0
0
Valmiera
Query!
Country [45]
0
0
Latvia
Query!
State/province [45]
0
0
Ventspils
Query!
Country [46]
0
0
Malaysia
Query!
State/province [46]
0
0
Kedah
Query!
Country [47]
0
0
Malaysia
Query!
State/province [47]
0
0
Perak
Query!
Country [48]
0
0
Malaysia
Query!
State/province [48]
0
0
Wilayah Persekutuan
Query!
Country [49]
0
0
New Zealand
Query!
State/province [49]
0
0
Auckland
Query!
Country [50]
0
0
New Zealand
Query!
State/province [50]
0
0
Wellington
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
Arkhangel'sk
Query!
Country [52]
0
0
Russian Federation
Query!
State/province [52]
0
0
Kazan
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Novosibirsk
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Smolensk
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Tomsk
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Vladimir
Query!
Country [57]
0
0
Serbia
Query!
State/province [57]
0
0
Kragujevac
Query!
Country [58]
0
0
Serbia
Query!
State/province [58]
0
0
Niš
Query!
Country [59]
0
0
Serbia
Query!
State/province [59]
0
0
Novi Sad
Query!
Country [60]
0
0
Singapore
Query!
State/province [60]
0
0
Singapore
Query!
Country [61]
0
0
South Africa
Query!
State/province [61]
0
0
Centurion
Query!
Country [62]
0
0
South Africa
Query!
State/province [62]
0
0
Gauteng
Query!
Country [63]
0
0
South Africa
Query!
State/province [63]
0
0
Limpopo
Query!
Country [64]
0
0
South Africa
Query!
State/province [64]
0
0
Benoni
Query!
Country [65]
0
0
South Africa
Query!
State/province [65]
0
0
Cape Town
Query!
Country [66]
0
0
South Africa
Query!
State/province [66]
0
0
Durban
Query!
Country [67]
0
0
South Africa
Query!
State/province [67]
0
0
Worcester
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Alicante
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Badalona
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Barakaldo
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Barcelona
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Córdoba
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Granada
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Terrassa
Query!
Country [76]
0
0
Thailand
Query!
State/province [76]
0
0
Bangkok
Query!
Country [77]
0
0
Thailand
Query!
State/province [77]
0
0
Khon Kaen
Query!
Country [78]
0
0
Thailand
Query!
State/province [78]
0
0
Mueang Nonthaburi
Query!
Country [79]
0
0
Turkey
Query!
State/province [79]
0
0
Ankara
Query!
Country [80]
0
0
Turkey
Query!
State/province [80]
0
0
Istanbul
Query!
Country [81]
0
0
Turkey
Query!
State/province [81]
0
0
Trabzon
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Ivano-Frankivs'k
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Kyiv
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Odesa
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Poltava
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
Sumy
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Zhytomyr
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Visterra, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs
oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen
support.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03040141
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
David Oldach, MD
Query!
Address
0
0
Visterra, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03040141
Download to PDF